Role of F-18 FDG PET/CT in non-conjunctival origin ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas

Hye Lim Park¹, Joo Hyun O²*, Sonya Youngju Park³, Seung-Eun Jung⁴, Gyeongsin Park⁵, Byung-Ock Choi⁶, Sung Hoon Kim⁷, Young-Woo Jeon⁷, Seok-Goo Cho⁸, Suk-Woo Yang⁹* and On behalf of Catholic University Lymphoma Group

Abstract

Background: Despite the widespread use of F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in the diagnosis and response assessment of patients with lymphoma, few studies have assessed its value in ocular adnexal lymphomas. The purpose of this study was to evaluate the role of FDG PET/CT in staging of non-conjunctival origin ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas (OAML). In addition, the diagnostic sensitivity of FDG PET/CT was compared with magnetic resonance imaging (MRI). FDG PET/CT of 123 consecutive patients with pathologically proven OAML between January 2009 and February 2016 were retrospectively reviewed. The patients with MALT lymphoma originating from conjunctiva were excluded. A total 50 patients with non-conjunctival origin OAML were assessed. Maximum standardized uptake value (SUVmax) and additional PET parameters were measured for all lesions. Sensitivity for primary tumor detection was compared with MRI.

Results: Ten patients had bilateral OAML and total 60 OAML lesions were analyzed. MRI was missing in one patient. The tumor locations were as follows: eyelid, 9; lacrimal gland, 18; orbit, 33. Fifty lesions (83.3%) were FDG-avid tumors with mean ± SD SUVmax 4.8 ± 2.4 (range 2.0~11.1). The mean SUVmax according to tumor location were as follows: eyelid, 3.7 ± 1.1 (2.8~5.3); lacrimal gland, 3.6 ± 1.4 (2.1~6.4); orbit, 5.7 ± 2.6 (2.0~11.1). Mean SUVmax among the 3 locations were statistically different (P = 0.010). The sensitivity was calculated as 83.1% (49/59) for FDG PET/CT and 89.8% (53/59) for MRI, which were statistically comparable (P = 0.219 by McNemar’s test). Seven of 50 patients (14%) were upstaged by detection of extraocular lesions by FDG PET/CT (1 kidney and lung, 1 tonsil, 4 cervical LNs, 1 sacral foramen).

Conclusion: 83.3% of the non-conjunctival origin OAML were FDG-avid tumors, with FDG PET/CT showing comparable sensitivity to that of MRI. FDG PET/CT detected unsuspected extraocular lymphoma involvement in 14% of the patients. FDG PET/CT performed for staging of non-conjunctival origin OAML may thus guide therapeutic management.

Keywords: Non-conjunctival MALT lymphoma, FDG PET/CT, staging

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Background
Ocular adnexal lymphoma (OAL) is the most common ocular tumor and constitutes 1% of non-Hodgkin lymphomas (NHL) and 8% of extranodal lymphomas [1]. The most common subtype of OAL is mucosa-associated lymphoid tissue (MALT) lymphomas, and the incidence of ocular adnexal MALT lymphoma (OAML) is high in Japan and Korea (80~98%) compared with Western countries (50~78%) [1–4]. Primary OAML involves conjunctiva, lacrimal gland, eyelid, and orbit. Most of primary OAML patients show localized disease (stage IE) at diagnosis and nodal involvement (5%) or systemic involvements (10~15%) are uncommon [1]. However, nodal involvement or systemic involvements are poor prognostic factors, and treatment beyond local radiation is needed for systemic disseminated disease [5].

FDG PET/CT protocol
All patients fasted for at least 6 h before the FDG PET/CT scan. An amount of 3.7~5.5 MBq/kg FDG was injected intravenously, and scanning began 60 min later. No intravenous contrast agent was administered. Images were acquired using a combined PET/CT in-line system (Biograph Duo, Biograph Truepoint, Biograph mCT, Siemens Medical Solutions; Discovery 710D, GE Healthcare). The acquisition time was 2~3 min per bed position. All patients were in the supine position during PET/CT scanning. Non-contrast-enhanced low-dose CT began at the orbitomeatal line and progressed to the proximal thigh using a standard protocol: 130 kVp, 80 mAs, 5-mm slice thickness (Biograph Duo); 120 kVp, 50 mAs, 5-mm slice thickness (Biograph Truepoint); 100~120 kVp, variable mAs adjusted by topographic image, 3-mm slice thickness (Biograph mCT); and 120 kVp, variable mAs adjusted by topographic image, 2.5-mm slice thickness (Discovery 710D). PET scans of the same body region followed immediately. The CT data were used for attenuation correction, and images were reconstructed using a standard ordered-subset expectation maximization algorithm.

Orbital MRI protocol
MRI scans were acquired with the patient in a prone position in a 3.0-T scanner (Magnetom Verio, Siemens Medical Solutions) equipped with an orbit coil using the following sequences: axial, turbo spin-echo T2-weighted imaging sequence and fat suppressed, pre- and post-contrast axial T1-weighted sequences obtained before and after Gd-DTPA injection.

Image analysis
FDG PET/CT scans were centrally reviewed by two nuclear medicine physicians, both with over 10 years of experience in ocular lymphoma PET/CT image interpretation, with knowledge of clinical diagnosis to reach a consensus. FDG PET/CT images were assessed using software, XD3 (Mirada Medical). FDG-avid tumor was defined as tumor showing discrete FDG uptake higher than background soft tissue on visual assessment, and we measured the maximum and mean standardized uptake value (SUVmax, SUVmean), and metabolic tumor volume (MTV). Threshold SUV of 2.0 was used for MTV computation. Total lesion glycolysis (TLG) was also obtained. Orbital MRI data were reviewed for this study by one radiologist aware of the tumor location. On MRI, OAML was defined as soft tissue mass with the conjunctivae alone were excluded. A total of 50 patients with non-conjunctival origin OAML were assessed (Fig. 1). This retrospective study was approved by Catholic Medical Center Institutional Review Board. Informed consent was waived.

Materials and methods
Patient population
We reviewed clinical records of patients with pathologically confirmed MALT lymphomas. A total of 123 consecutive patients with OAML had pre-treatment FDG PET/CT scans between January 2009 and February 2016. Seventy-three patients with MALT lymphoma involving the conjunctivae alone were excluded. A total of 50 patients with non-conjunctival origin OAML were assessed (Fig. 1). This retrospective study was approved by Catholic Medical Center Institutional Review Board. Informed consent was waived.

FDG PET/CT protocol
All patients fasted for at least 6 h before the FDG PET/CT scan. An amount of 3.7~5.5 MBq/kg FDG was injected intravenously, and scanning began 60 min later. No intravenous contrast agent was administered. Images were acquired using a combined PET/CT in-line system (Biograph Duo, Biograph Truepoint, Biograph mCT, Siemens Medical Solutions; Discovery 710D, GE Healthcare). The acquisition time was 2~3 min per bed position. All patients were in the supine position during PET/CT scanning. Non-contrast-enhanced low-dose CT began at the orbitomeatal line and progressed to the proximal thigh using a standard protocol: 130 kVp, 80 mAs, 5-mm slice thickness (Biograph Duo); 120 kVp, 50 mAs, 5-mm slice thickness (Biograph Truepoint); 100~120 kVp, variable mAs adjusted by topographic image, 3-mm slice thickness (Biograph mCT); and 120 kVp, variable mAs adjusted by topographic image, 2.5-mm slice thickness (Discovery 710D). PET scans of the same body region followed immediately. The CT data were used for attenuation correction, and images were reconstructed using a standard ordered-subset expectation maximization algorithm.

Orbital MRI protocol
MRI scans were acquired with the patient in a prone position in a 3.0-T scanner (Magnetom Verio, Siemens Medical Solutions) equipped with an orbit coil using the following sequences: axial, turbo spin-echo T2-weighted imaging sequence and fat suppressed, pre- and post-contrast axial T1-weighted sequences obtained before and after Gd-DTPA injection.

Image analysis
FDG PET/CT scans were centrally reviewed by two nuclear medicine physicians, both with over 10 years of experience in ocular lymphoma PET/CT image interpretation, with knowledge of clinical diagnosis to reach a consensus. FDG PET/CT images were assessed using software, XD3 (Mirada Medical). FDG-avid tumor was defined as tumor showing discrete FDG uptake higher than background soft tissue on visual assessment, and we measured the maximum and mean standardized uptake value (SUVmax, SUVmean), and metabolic tumor volume (MTV). Threshold SUV of 2.0 was used for MTV computation. Total lesion glycolysis (TLG) was also obtained. Orbital MRI data were reviewed for this study by one radiologist aware of the tumor location. On MRI, OAML was defined as soft tissue mass with
high signal intensity (SI) on T2-weighted sequence, low SI on T1-weighted sequence, and homogeneous enhancement on gadolinium-enhanced sequence [13]. For the diagnosis of lymphoma involvement at an extraocular lesion detected by PET/CT, histologic confirmation was performed when possible (n = 3). In the cases without biopsy confirmation, the final diagnosis was made by imaging and clinical follow-up (n = 4). Clinically, lesions showing unequivocal response after systemic chemotherapy were considered positive for lymphoma.

**Statistical analysis**

Statistical analysis was carried out using the Statistical Package for Social Sciences (SPSS statistics 24) software. Mann-Whitney U test with Bonferroni correction was performed for comparison among SUVmax, SUVmean, MTV, and TLG of primary tumors categorized by location. Sensitivity of PET/CT and MRI were compared by the McNemar’s test. P values < 0.05 were considered to indicate statistical significance.

**Results**

Fifty patients with non-conjunctival OAML were included in this study (30 male and 20 female, median age 53.5, range 25~80). Ten patients had bilateral OAML (eyelid, 2; lacrimal gland, 5; and orbit, 3), and a total of 60 ocular lesions were assessed. The locations of OAML were as follows: eyelid, 9; lacrimal gland, 18; orbit, 33. Patient characteristics are presented in Table 1.

On FDG PET/CT scan, 50 lesions (83.3%) were FDG-avid with mean ± standard deviation (SD) SUVmax of 4.8 ± 2.4 (range 2.0~11.1). Locations of FDG-avid tumors were 4 of eyelid, 18 of lacrimal gland, and 28 of orbit. The mean SUVmax, SUVmean, MTV (cm³), and TLG according to tumor location are presented in Table 2. Mean SUVmax, SUVmean, MTV (cm³), and TLG were statistically different by Kruskal-Wallis test. The differences of each group were calculated by Mann-Whitney U test using Bonferroni correction, and mean SUVmax between lacrimal gland and orbit was statistically different (P = 0.012) (Fig. 2). Also, mean SUVmean, MTV, and TLG between lacrimal gland and orbit were significantly different (P < 0.001, P = 0.015, and P = 0.006, respectively). There were 10 OAML lesions in nine patients with imperceptible FDG uptake (5 lesions in eyelid and 5 lesions in orbit).

MRI was missing in one patient. For the evaluation of sensitivity, 59 lesions were analyzed. On orbital MRI, 53 lesions were detected and the locations were as follows: eyelid, 6; lacrimal gland, 18; orbit, 29. The sensitivity for
the ocular lesions was calculated as 83.1% (49/59) for FDG PET/CT and 89.8% (53/59) for MRI, which were statistically comparable ($P = 0.219$ by McNemar’s test).

Seven of 50 patients (14%) were upstaged by detection of extraocular lesions by FDG PET/CT to either IIE or IVE (Fig. 3). Of the seven patients, one patient had positive bone marrow biopsy result, but the 6 other patients were upstaged by FDG PET/CT findings alone. Characteristics of extraocular lesions detected by FDG PET/CT are presented in Table 3. Neck nodes were the most commonly involved extraocular sites.

In this study population, there were 8 patients finally diagnosed with stage IVE: 5 patients had bone marrow involvement confirmed by bone marrow biopsy, and 3 patients had disseminated disease. Of the 3 patients with disseminated disease, one patient had multiple skin lesions without FDG uptake that was confirmed by biopsy. Two patients had highly FDG-avid multi-organ involvement.

### Discussion

Marginal zone lymphoma often clinically presents as extra-nodal lesions, and rarely presents as nodal disease. OAML is one manifestation of extranodal lymphoma [2, 14]. There were a few studies about the role of FDG PET/CT in diagnosis and staging of OAL [15–18], and the role of FDG PET/CT in treatment response evaluation [17, 19]. To our knowledge, this is the first FDG PET/CT study evaluating the findings and the role of FDG PET/CT in staging of non-conjunctival OAML.

Our institution is a tertiary referral hospital with External Eye Disease Clinic at the Ophthalmology Center as well as Lymphoma Multidisciplinary Outpatient Clinic. The sites of OAML in our institution were as follows: conjunctiva 59% (73/123), orbit 26.8% (30/123), lacrimal gland 10.6% (13/123), and eyelid 5.3% (7/123), reporting higher incidence of conjunctival lesion than a previous report [1]. OAL was reported to show bilateral involvement in 7 to 24% [19], and our study patients had bilateral lymphoma in 10%.

National Cancer Center Network (NCCN) guideline (v. 2018.4) suggests that chest, abdomen, and pelvic CT and/or FDG PET/CT be done for essential workup [20]. FDG PET/CT is routinely performed for staging of patients with lymphoma at our institution. FDG PET/CT showed positive FDG uptake in 83.3% of non-conjunctival OAML and a detection rate similar to that of orbital MRI. Previous studies with OAML including conjunctival origin reported detection rates between 38.1 and 86% [15, 18, 21]. In our study, FDG uptake intensity varied according to the involved sites: lymphoma of orbit showed significantly higher uptake than

### Table 1 Patient characteristics

| Characteristics                  | Number (%) |
|----------------------------------|------------|
| Median age (range)               | 53.3 years (25–80) |
| Sex                              |            |
| Male                             | 30 (60.0)  |
| Female                           | 20 (40.0)  |
| Ann Arbor stage                  |            |
| IE-IIE                           | 41 (82.0)  |
| IIIE-IVE                         | 9 (18.0)   |
| LDH                              |            |
| Normal                           | 46 (92.0)  |
| Elevated                         | 4 (8.0)    |
| ECOG Performance status          |            |
| 0–1                              | 50 (100.0) |
| 2–4                              | 0 (0.0)    |
| International prognostic index   |            |
| 0–1                              | 40 (80.0)  |
| 2                                | 9 (18.0)   |
| 3                                | 1 (2.0)    |
| 4                                | 0 (0.0)    |
| Location of OAML                 |            |
| Eyelid                           | 7 (14.0)   |
| Lacrimal gland                   | 13 (26.0)  |
| Orbit                            | 30 (60.0)  |
| Laterality                       |            |
| Unilateral (right: left)         | 40 (25:15) |
| Bilateral                        | 10         |
| Initial treatment                |            |
| Chemotherapy                     | 37 (74.0)  |
| Radiation                        | 6 (12.0)   |
| Chemotherapy and radiation       | 6 (12.0)   |
| Excision                         | 1 (2.0)    |

*LDH lactate dehydrogenase
ECOG Eastern Cooperative Oncology Group
OAML ocular adnexal mucosa-associated lymphoid tissue lymphoma

### Table 2 The mean ± standard deviation and range of PET parameters according to the location of lymphoma

| Location          | Eyelid               | Lacrimal gland     | Orbit                  |
|-------------------|----------------------|--------------------|------------------------|
| SUVmax            | 3.7 ± 1.1 (2.8–5.3)  | 3.6 ± 1.4 (2.1–6.4) | 5.7 ± 2.6 (2.0–11.1)  |
| SUVmean           | 2.5 ± 0.7 (1.9–3.5)  | 2.2 ± 0.7 (1.5–3.8) | 3.4 ± 1.2 (1.7–6.4)   |
| MTV (cm³)         | 2.8 ± 1.0 (2.1–4.2)  | 2.6 ± 2.2 (0.2–7.0) | 7.1 ± 6.8 (0.2–26.0)  |
| TLG               | 7.3 ± 3.5 (4.0–10.5) | 7.0 ± 7.4 (0.3–25.1)| 28.1 ± 31.7 (0.4–121.7)|
lymphoma of eyelid or lacrimal gland. The 16.7% of the lesions without FDG uptake were either located in the eyelids with very small tumor volumes or in the orbit, and distinction from the intense FDG uptake in the ocular muscles was difficult. It remains to be seen how the recent advances with digital PET may improve this sensitivity.

Previous reports showed extraocular involvement in 10–15% of patients with OAL [1]. For primary OAML, Thuro et al. reported extraocular involvement on FDG
PET/CT of up to 28.6% of patients [21]. In our study, seven (14%) of primary OAML patients had extraocular involvement detected by FDG PET/CT and were upstaged to stage IIE (n = 4) or stage IVE (n = 3). There were 8 patients with stage IVE, including the three patients with distant lesions detected by FDG PET/CT. PET/CT did not detect distant lesions in 5 patients: 4 with positive bone marrow involvement and 1 with histologically confirmed multiple skin lesions. Our institution routinely performs bone marrow biopsy at the staging workup, as one report demonstrated positive bone marrow involvement in 12% of OAML patients [21]. Data is lacking to suggest bone marrow biopsy can be omitted in OAML patients with FDG PET/CT imaging performed at diagnosis.

Though FDG PET/CT has limited evidence to replace bone marrow biopsy [22], PET/CT has high sensitivity for detecting nodal and systemic organ involvement. Our findings showing 14% of patients with extraocular involvement further emphasizes the diagnostic value of staging FDG PET/CT. Frontline therapy of OAML is radiation therapy [4, 5], but once there is systemic involvement, chemotherapy is performed. In our study, the treatment plan changed from radiotherapy to chemotherapy in 6 patients. This study included six patients who received both chemotherapy followed by consolidative radiation therapy due to bulky tumor volume or insufficient treatment response of chemotherapy. In one recent study, chemotherapy including rituximab showed good treatment response for both ocular and extraocular lesions [5]. If radiation therapy is performed after orbit MRI without systemic evaluation, extraocular lesions will go undetected and thus untreated. Therefore, FDG PET/CT has a role in initial staging and planning of treatment strategy in patients with non-conjunctival OAML, which has higher rate of systemic involvement and recurrence rate compared with conjunctival OAML [23, 24].

Prognostic value of baseline FDG PET/CT has been reported in previous studies, and we plan on performing analysis of long-term clinical outcome with a larger study population [10, 25, 26].

**Conclusion**

In patients with non-conjunctival origin OAML, 14% of patients were upstaged by FDG PET/CT and received systemic chemotherapy instead of radiation therapy. FDG PET/CT should be performed for staging of non-conjunctival origin OAML to guide the therapeutic plan.

**Abbreviations**

FDG: Fluorodeoxyglucose; MALT: Mucosa-associated lymphoid tissue;
MRI: Magnetic resonance imaging; MTV: Metabolic tumor volume;
NCCN: National Cancer Center Network; NHL: Non-Hodgkin lymphoma;
OAL: Ocular adnexal lymphoma; OAML: Ocular adnexal MALT lymphoma;
PET/CT: Positron-emission tomography/computed tomography; SD: Standard deviation; SI: Signal intensity; SUVmax: Maximum standardized uptake value; SUVmean: Mean standardized uptake value; TLG: Total lesion glycolysis

**Acknowledgements**

Not applicable.

**Authors’ contributions**

HLP, SY.P and JHO participated in the study design, collecting data and data analysis. HLP and JHO prepared the manuscript and data interpretation. SEJ, GP, BOC, YJ and SHK contributed to the data analysis and interpretation. JHO, SGC and SWY supervised the project and reviewed the manuscript. All authors read and approved the final manuscript.
Received: 12 July 2019 Accepted: 20 September 2019
Published online: 21 November 2019

References
1. Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa. Blood. 2009;114:501–10.
2. Lee SE, Paik JS, Cho WK, Choi BO, Lee SN, Jung SE, et al. Feasibility of the TNM-based staging system of ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Am J Hematol. 2011;86:262–6.
3. Cho EY, Han JJ, Ree HJ, Ko YH, Kang YK, Ahn HS, et al. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone b-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. Am J Hematol. 2003;73:87–96.
4. Cho WK, Lee SE, Paik JS, Cho SG, Yang SW. Risk potentiality of frontine radiotherapy associated cataract in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma. Korean J Ophthalmol. 2013;27:243–8.
5. Kim SY, Yang SW, Lee WS, Yang JW, Oh SY, Ahn HB, et al. Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study. Oncotarget. 2017;8:68583–90.
6. Kim HJ, Lee R, Choi H, Paeng JC, Cheon GJ, Lee DS, et al. Application of Quantitative Indexes of FDG PET to Treatment Response Evaluation in Indolent Lymphoma. Nucl Med Mol Imaging. 2018;52:342–9.
7. Barrington SF, Mikaeleng N, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.
8. Weiler-Sagle M, Busleev O, Eppelbaum R, Dann EJ, Haim N, Avril I, et al. (18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25–30.
9. Treglia G, Zucca E, Sadeghii R, Cavalli F, Giovanella L, Ceriani L. Detection rate of fluorine-18-fluorodesoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis. Hematol Oncol. 2015;33:113–24.
10. Albano D, Bosio G, Giubini R, Bertagna F. 18F-FDG PET/CT and extragastic MALT lymphoma: role of Ki-67 score and plasmacytic differentiation. Leuk Lymphoma. 2017;58:2328–34.
11. Albano D, Bertoli M, Ferro P, Follancio F, Gianolli L, Picchio M, et al. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. Eur J Nucl Med Mol Imaging. 2017;44:589–97.
12. Jung SK, Paik JS, Jung SE, Park G, Choi BO, Oh JK, et al. Suggestion of response evaluation criteria in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma (QAML). Ann Hematol. 2015;94:1185–93.
13. Maksimovic O, Bethge WA, Pintoft JP, Vogel M, Clausen CD, Bares R, et al. Marginal zone B-cell non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue type: imaging findings. AJR Am J Roentgenol. 2008;191:921–30.
14. Kim JH, Jeon YW, Choi BO, Park G, Hong YK, Yang SW, et al. Intracranial relapse as a solitary mass of ocular adnexal lymphoma of the mucosa-associated lymphoid tissue type. Korean J Intern Med. 2018;33:224–7.
15. English JF, Sullivan TJ. The role of FDG-PET in the diagnosis and staging of ocular adnexal lymphoproliferative disease. Orbit. 2015;34:284–91.
16. Valenzuela AA, Allen C, Grimes D, Wong D, Sullivan TJ. Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease. Ophthalmology. 2006;113:2331–7.
17. Gayed I, Etkandari MF, McLaughlin P, Pro B, Diba R, Esmaili B. Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalimc Surg Lasers Imaging. 2007;38:19–25.
18. Zanni M, Moulin-Romsee G, Servis V, Valideri P, Bénamor M, Plancher C, et al. Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience. Hematology. 2012;17:764–8.
19. Fuji H, Tanaka H, Nomoto Y, Harata N, Dota S, Isogai J, et al. Usefulness of 18F-FDG PET/CT for evaluating response of ocular adnexal lymphoma to treatment. Medicine (Baltimore). 2018;97:e0534.
20. NCCN Clinical Practice Guidelines in oncology B-Cell Lymphomas Version 4. 2018. 2018.
21. Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, et al. Rates of positive findings on positron emission tomography and bone marrow biopsy in patients with ocular adnexal lymphoma. Ophthalmic Plast Reconstr Surg. 2017;33:355–60.
22. Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RA, de Klerk JM. Bone marrow 18F-fluoroo-2-deoxy-D-glucose positron emission tomography/ computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol. 2014;89:276–31.
23. Johnson TE, Tse DT, Byrne GE Jr, Restrepo A, Whitcomb CC, Voigt W, et al. Ocular-adnexal lymphoid tumors: a clinicopathologic and molecular genetic study of 77 patients. Ophthalmol Plast Reconstr Surg. 2017;33:355–60.
24. Martinet S, Oszahrn M, Belkacemi Y, Landmann C, Poortmans P, Oehlere C, et al. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55:892–9.
25. Vaxman I, Bernstine H, Kleinstern G, Hendin N, Avivi I, et al. FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma. Hematol Oncol. 2019;37:168–75.
26. Albano D, Bosio G, Camoni L, Farina M, Re A, Tucci A, et al. Prognostic role of baseline (18)F-FDG PET/CT parameters in MALT lymphoma. Hematol Oncol. 2019;37:39–46.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.